Form 4: United Therapeutics CEO Trades Shares

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock on June 24, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp. (UTHR), reported a series of transactions on June 24, 2026.
• These transactions involved the exercise of stock options and the subsequent sale of common stock.
• The exercise price for the stock options was $135.42.
• A total of 9,500 shares were acquired through option exercise.
• Following these transactions, Rothblatt's direct beneficial ownership of common stock decreased by 9,500 shares, resulting in 40,513 directly owned shares.
• The sales of common stock occurred at weighted average prices ranging from $545.46 to $553.48.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on November 7, 2025, which is set to continue until the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026, whichever comes first.
• Rothblatt also holds a significant number of shares indirectly through trusts and by her spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details routine insider transactions executed under a pre-arranged plan, without indicating significant positive or negative shifts in the insider's view of the company's prospects.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a structured and planned approach to stock sales, which can mitigate insider trading concerns.
• The exercise price of $135.42 is significantly lower than the sale prices, indicating a substantial profit on the exercised options.
• The CEO continues to hold a substantial number of shares indirectly through various trusts and by her spouse, suggesting continued long-term commitment to the company.

Negatives

• A significant number of shares (9,500 acquired via option exercise and subsequent sales) were disposed of by the CEO.
• The weighted average sale prices, while high, represent a reduction in the CEO's direct holdings.

Risks

• The 10b5-1 plan has an expiration date of December 31, 2026, or upon exercise of all remaining options, which could lead to further sales or changes in holdings.
• The reliance on trusts for indirect ownership introduces complexity in understanding ultimate beneficial ownership and control.

Future Outlook

The 10b5-1 trading plan is active until December 31, 2026, or until all 1,734,410 stock options expire on March 15, 2027. This indicates potential for further transactions within this period.

Management Comments

• The exercise of stock options and sale of resulting shares were pursuant to a pre-arranged 10b5-1 trading plan.
• The reporting person undertakes to provide full information regarding the number of shares and prices upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The use of a 10b5-1 plan by a CEO like Martine A. Rothblatt at United Therapeutics is common practice for managing personal stock portfolios in a compliant manner, especially when dealing with significant option grants.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive may be scrutinized, but the use of a 10b5-1 plan suggests a pre-determined strategy rather than a reaction to non-public information.
• Employees: The CEO's stock transactions do not directly impact employee compensation or benefits but can influence employee morale based on perceptions of executive confidence.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Continued execution of the 10b5-1 trading plan until its expiration or completion of option exercises.
• Potential for further Form 4 filings to report subsequent transactions.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Martine A. Rothblatt, Stock Options, Common Stock, Insider Trading, 10b5-1 Plan, Beneficial Ownership, CEO Transactions